(Q41445502)

30 September 2017

1 reference

title

Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia (English)

1 reference

30 September 2017

1 reference

K L Goa

1

1 reference

30 September 2017

L B Barradell

series ordinal

2

1 reference

30 September 2017

G L Plosker

series ordinal

3

1 reference

30 September 2017

publication date

1 November 1996

1 reference

30 September 2017

1 reference

30 September 2017

volume

52

1 reference

30 September 2017

issue

5

1 reference

30 September 2017

page(s)

725-753

1 reference

Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolaemia

30 September 2017

cites work

1 reference

12 December 2020

Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia

1 reference

12 December 2020

Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers

1 reference

12 December 2020

Bezafibrate-induced neutropenia

1 reference

12 December 2020

Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia

1 reference

12 December 2020

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

1 reference

12 December 2020

Peripheral neuropathy with bezafibrate

1 reference

12 December 2020

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia

1 reference

12 December 2020

Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy

1 reference

12 December 2020

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia

1 reference

12 December 2020

Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients

1 reference

12 December 2020

Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

12 December 2020

Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

Bezafibrate in the treatment of hyperlipidemia

1 reference

12 December 2020

High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia

1 reference

12 December 2020

A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia

1 reference

12 December 2020

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

1 reference

12 December 2020

Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination

1 reference

12 December 2020

Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient

1 reference

12 December 2020

Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs

1 reference

12 December 2020

Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin

1 reference

12 December 2020

Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia

1 reference

12 December 2020

Blood rheology changes during bezafibrate treatment

1 reference

12 December 2020

Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.

1 reference

12 December 2020

Cost implications of lipid-lowering treatments

1 reference

12 December 2020

Prevention of restenosis by bezafibrate after successful coronary angioplasty

1 reference

12 December 2020

[Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study]

1 reference

12 December 2020

Open-label study to assess the efficacy, safe, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia

1 reference

12 December 2020

Fibrinogen and atherosclerosis.

1 reference

12 December 2020

Bezafibrate therapy and biliary lipids: effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia

1 reference

12 December 2020

Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment

1 reference

12 December 2020

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia

1 reference

12 December 2020

Fibric acids: effects on lipids and lipoprotein metabolism

1 reference

12 December 2020

A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting

1 reference

12 December 2020

Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.

1 reference

12 December 2020

The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia

1 reference

12 December 2020

Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients

1 reference

12 December 2020

Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

1 reference

12 December 2020

Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Comparative study of bezafibrate and probucol in hyperlipidaemia

1 reference

12 December 2020

Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia

1 reference

12 December 2020

Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man

1 reference

12 December 2020

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis

1 reference

12 December 2020

Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate

1 reference

12 December 2020

Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate

1 reference

12 December 2020

1 reference

12 December 2020

Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction

1 reference

12 December 2020

Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia

1 reference

12 December 2020

Does lowering cholesterol cause cancer?

1 reference

12 December 2020

Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial

1 reference

12 December 2020

Bezafibrate-induced myopathy: no evidence for defects in muscle metabolism

1 reference

12 December 2020

Bezafibrate induced rhabdomyolysis

1 reference

12 December 2020

Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form

1 reference

12 December 2020

Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia

1 reference

12 December 2020

Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention

1 reference

12 December 2020

Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia.

1 reference

12 December 2020

Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia

1 reference

12 December 2020

Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells

1 reference

12 December 2020

Disparate effects of a triglyceride lowering diet and of bezafibrate on the HDL system: a study in patients with hypertriglyceridaemia and low HDL-cholesterol levels

1 reference

12 December 2020

Mechanism of action of fibrates

1 reference

12 December 2020

Triglyceride-rich lipoproteins and the progression of coronary artery disease

1 reference

12 December 2020

Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson)

1 reference

12 December 2020

Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia

1 reference

12 December 2020

Elevated blood concentrations of cyclosporine and kidney failure after bezafibrate in renal graft recipient

1 reference

12 December 2020

Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation

1 reference

12 December 2020

Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia

1 reference

12 December 2020

Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition

1 reference

12 December 2020

Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients

1 reference

12 December 2020

Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men.

1 reference

12 December 2020

Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

1 reference

12 December 2020

Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients

1 reference

12 December 2020

Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients

1 reference

12 December 2020

Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia

1 reference

12 December 2020

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease

1 reference

12 December 2020

Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients

1 reference

12 December 2020

[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration]

1 reference

12 December 2020

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

1 reference

12 December 2020

Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience

1 reference

12 December 2020

Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation

1 reference

12 December 2020

The Helsinki Heart Study: an 8.5-year safety and mortality follow-up

1 reference

12 December 2020

Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia

1 reference

12 December 2020

Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia

1 reference

12 December 2020

The effects of fibrates on lipoprotein and hemostatic coronary risk factors

1 reference

12 December 2020

Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study

1 reference

12 December 2020

The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study

1 reference

12 December 2020

Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: normalization with bezafibrate therapy

1 reference

12 December 2020

Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia

1 reference

12 December 2020

Disposition pharmacokinetics of bezafibrate in man

1 reference

12 December 2020

Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate

1 reference

12 December 2020

Effects of bezafibrate on biosynthesis of cholesterol and on degradation of native and acetylated low-density lipoproteins in incubated human monocytes

1 reference

12 December 2020

Treatment of diabetes: the effect on serum lipids and lipoproteins

1 reference

12 December 2020

Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate

1 reference

12 December 2020

Fibrinogen in ischaemic heart disease

1 reference

12 December 2020

Bezafibrate induced reduction of renal function in a renal transplant recipient.

1 reference

12 December 2020

Bezafibrate affects lipid, lipo- and apolipoprotein pattern in non-insulin-dependent diabetic patients

1 reference

12 December 2020

High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate

1 reference

12 December 2020

Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients

1 reference

12 December 2020

Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial

1 reference

12 December 2020

Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control

1 reference

12 December 2020

Therapeutic interventions to lower plasma fibrinogen concentration

1 reference

12 December 2020

A case of acute rhabdomyolysis and acute renal insufficiency caused by the simultaneous use of furosemide and bezafibrate

1 reference

12 December 2020

[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]

1 reference

12 December 2020

Fibrates and triglyceride metabolism

1 reference

12 December 2020

Bezalip-induced anaphylaxis

1 reference

12 December 2020

The hypertriglyceridemias: Risk and management. Epidemiology

1 reference

12 December 2020

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

1 reference

12 December 2020

Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure associated with bezafibrate treatment

1 reference

12 December 2020

Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients

1 reference

12 December 2020

Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Free cholesterol concentrations in the high-density lipoprotein subfraction-3 as a risk indicator in patients with angiographically documented coronary artery disease

1 reference

12 December 2020

Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy]

1 reference

12 December 2020

Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives

1 reference

12 December 2020

The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia

1 reference

12 December 2020

Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.

1 reference

12 December 2020

Influences of lipid-modifying agents on hemostasis

1 reference

12 December 2020

New approaches to the prevention of atherosclerosis

1 reference

12 December 2020

HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil

1 reference

12 December 2020

Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.

1 reference

12 December 2020

Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.

1 reference

12 December 2020

Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis

1 reference

12 December 2020

Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia

1 reference

12 December 2020

Bezafibrate-induced rhabdomyolysis

1 reference

12 December 2020

Severe type III hyperlipoproteinemia in two patients maintained on chronic hemodialysis

1 reference

12 December 2020

Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group

1 reference

12 December 2020

[Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia]

1 reference

12 December 2020

Reduction of Lp(a) plasma levels by bezafibrate

1 reference

12 December 2020

Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients

1 reference

12 December 2020

Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.

1 reference

12 December 2020

Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen

1 reference

12 December 2020

[Reductions in lipid fraction plasma levels induced by simvastatin and bezafibrate. Brazilian multicenter study]

1 reference

12 December 2020

Carcinogenicity of lipid-lowering drugs

1 reference

12 December 2020

Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia

1 reference

12 December 2020

Severe reversible renal failure with bezafibrate.

1 reference

12 December 2020

Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment

1 reference

12 December 2020

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

1 reference

12 December 2020

Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis

1 reference

12 December 2020

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

12 December 2020

10.2165/00003495-199652050-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

30 September 2017

1011462884

0 references

1 reference